Nasus Pharma is trading 14.05% down at $3.51 after no confirmed company-specific announcement dated September 1, 2026 emerged; the decline appears tied to broad risk-off sentiment as renewed U.S.-Iran tensions lifted oil prices and pressured equities.
- Rising Treasury yields and Japan’s 10-year yield reaching 3% intensified concerns about inflation and tighter monetary policy.
- Healthcare sector strength does not explain this company-specific decline.